Aytu Biopharma (AYTU) Interest Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 15 years of Interest Expenses data on file, last reported at $436000.0 in Q1 2026.

• Interest Expenses for Q1 2026 came in at $436000.0, down 51.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 46.95% YoY), and the FY2025 annual result was $3.7 million, down 26.8% from the prior year.
• Interest Expenses eased to $436000.0 in Q1 2026 per AYTU's latest filing, from $560000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $1.3 million in Q3 2023 and troughed at $436000.0 in Q1 2026.
• A 4-year average of $934000.0 and a median of $994000.0 in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2026: Interest Expenses slipped 14.77% in 2024, then plunged 51.56% in 2026.
• A 4-year view of Interest Expenses shows it stood at $1.3 million in 2023, then fell by 14.77% to $1.1 million in 2024, then sank by 48.1% to $560000.0 in 2025, then decreased by 22.14% to $436000.0 in 2026.
• Business Quant data shows AYTU's Interest Expenses at $436000.0 in Q1 2026, $560000.0 in Q4 2025, and $516000.0 in Q3 2025.